CGTX cogrx.com: Accounting Value per Share

Cognition Therapeutics (CGTX) focuses on conducting its own clinical trials, relying on government funding and partnerships with scientific centers. The business is based on the development of small molecules to combat toxic proteins associated with Alzheimer's disease. The current figure is 0.35. This price trend chart below illustrates the asset's dynamics against a backdrop of geopolitical risks that hinder international logistics and access to foreign patients.

For Cognition Therapeutics (CGTX), the capital per share level reflects the business's financial stability during the development of CNS drugs and its dependence on the results of synaptic protection trials. This indicator is calculated as the difference between all company assets and liabilities divided by the number of shares, allowing an investor to assess the real value of net assets and determine the degree of the stock's overvaluation.